Investors in Paris gave a strong boost to Transgene (NASDAQ: TGEN) on Thursday, with the company’s shares climbing roughly 20% in early trading. The surge followed the release of encouraging Phase 1 data on TG4050, a personalized vaccine aimed at preventing relapse in patients with high‑risk head and neck cancer after surgery and chemoradiotherapy.
What the trial showed
The small, open‑label study enrolled 32 participants – 16 received TG4050 and 16 were placed in a control arm receiving standard follow‑up care. According to Transgene’s press release, every patient who received the vaccine remained disease‑free through the reporting period, while three relapses occurred among the control group.
Analysts highlighted the result as a promising signal for a disease area where recurrence rates are high. Kempen analyst Chiara Montironi described the longer follow‑up as providing a “robust dataset” that supports TG4050’s potential to prevent relapse, a factor that could drive future commercial interest.
Scientific background
TG4050 is built in partnership with Japan’s NEC Corp, which supplies artificial‑intelligence algorithms to identify tumor‑specific antigens for each patient. The vaccine is designed to train the immune system to recognize and attack any remaining cancer cells after the primary treatment, a strategy that aligns with the broader trend toward individualized cancer immunotherapies.
While the data are encouraging, the study’s authors cautioned that the sample size is limited and the findings do not yet meet the threshold for statistical significance. Larger, randomized trials will be needed to confirm efficacy and safety before regulatory approval can be pursued.
Next steps for Transgene
Transgene said it expects to release Phase 2 immunological data in the second half of 2026, with two‑year efficacy results slated for the first quarter of 2028. If those later‑stage results confirm the early promise, TG4050 could become a valuable addition to the growing portfolio of personalized cancer vaccines, joining efforts from companies such as Moderna, which recently reported a dramatic reduction in recurrence risk for its melanoma vaccine.
For now, the market’s positive reaction underscores investor confidence in the company’s technology platform and its potential to address an unmet medical need in oncology.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
